CClinicalTrials.gg
CompletedNCT03458767PALMS-IIUpdated Jul 17, 2018

A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology

An interventional study of Eight weekly 90-minute group educational sessions in Multiple Sclerosis, sponsored by University of Texas at Austin. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-07-17.

Sponsored by University of Texas at Austin · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

Development and pilot testing of a cognitive self-management intervention for persons with multiple sclerosis (PwMS) emphasizing physical activity (PA) delivered via web-based video conference.

Read the detailed description

The primary objective of this study is to develop and pilot test an innovative cognitive self-management intervention for PwMS delivered via web-based video conferencing. Data derived from interviews will be used to guide the adaptation of Stuifbergen's 8-week Memory, Attention, and Problem-Solving Skills in MS (MAPSS-MS) intervention to be delivered via web-based video conferencing. The adapted MAPSS-MS intervention will be feasibility tested in small groups of PwMS. Outcome variables include: (1) neurocognitive function assessed using the NIH Toolbox®, a comprehensive set of psychometrically sound neuro-behavioral measures that quickly assesses cognitive functions using an iPad, (2) objective PA and sleep using Actigraph™ accelerometers, (3) self-reported sleep, depression, and fatigue using the Patient-Reported Outcome Measurement Information System (PROMIS), and (4) MS specific self-management using the Multiple Sclerosis Self-Management Scale (MSSM). Community-residing PwMS, age 21 to 70, will be recruited from Central Texas to participate in Phase 1 interviews (n=5) and Phase 2 pilot testing (n=20) of the adapted version of the 8-week MAPSS-MS cognitive self-management intervention emphasizing PA delivered via web-based video conferencing. In Phase 2 pilot testing (n=20), an intervention group (n=10) will be compared to an "enhanced usual care" control group (n=10).

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • Cognitive function
  • Physical activity
  • Self-management
03

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of clinically definite MS documented by their healthcare provider
  • Age 21 to 70
  • Capable of understanding and complying with the study protocol
  • Able to read and write in English
  • Stable disease at the time of entry into the study (relapse free for at least 90 days)
  • Willing to participate in an 8-week study promoting physical activity, MS self-management and compensatory cognitive strategies, and data collection
  • Have subjective concerns about their cognitive functioning (score ≥ 10 on the 20-item Perceived Deficits Questionnaire)
  • Any gender
  • Any ethnic/racial group

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or plan to be
  • Diagnosed with cardiovascular or respiratory disease, other medical causes of dementia or other neurological disorders that may impact cognition or emotions
  • Evidence of major psychiatric disorder
  • Major functional limitations that preclude them from participating in the study
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Intervention group

    Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.

    Behavioral: Eight weekly 90-minute group educational sessions

  • No intervention
    Control group

    Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).

Interventions

  • BehavioralEight weekly 90-minute group educational sessions

    Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.

05

What researchers measure

Primary outcomes

  1. Change from Baseline NIH Toolbox Picture Vocabulary Test at 8-weeks (post-intervention)

    Test of vocabulary knowledge

    Time frame: Baseline and 8-weeks (post intervention)

  2. Change from Baseline NIH Toolbox Oral Reading Recognition at 8-weeks (post-intervention)

    Test of oral reading (decoding) skills

    Time frame: Baseline and 8-weeks (post intervention)

  3. Change from Baseline NIH Toolbox Flanker Inhibitory Control and Attention Test at 8-weeks (post-intervention)

    Test of executive function - the capacity to plan, organize and monitor the execution of behaviors that are strategically directed in a goal-oriented manner) and attention (allocation of one's limited capacities to deal with an abundance of environmental stimulation) test.

    Time frame: Baseline and 8-weeks (post intervention)

  4. Change from Baseline NIH Toolbox Dimensional Change Card Sort Test at 8-weeks (post-intervention)

    Test of attention - the allocation of one's limited capacities to deal with an abundance of environmental stimulation) test.

    Time frame: Baseline and 8-weeks (post intervention)

  5. Change from Baseline NIH Toolbox List Sorting Working Memory Test at 8-weeks (post-intervention)

    Test of working memory - the capacity of an individual to hold information in a short-term buffer and manipulate the information.

    Time frame: Baseline and 8-weeks (post intervention)

  6. Change from Baseline NIH Toolbox Oral Symbol Digit Test at 8-weeks (post-intervention)

    Test of processing speed - the amount of time it takes to mentally process a set amount of information, or the amount of information that can be processed within a certain unit of time. It is a measure that reflects mental efficiency.

    Time frame: Baseline and 8-weeks (post intervention)

  7. Change from Baseline NIH Toolbox Pattern Comparison Processing Speed Test at 8-weeks (post-intervention)

    Test of processing speed - the amount of time it takes to mentally process a set amount of information, or the amount of information that can be processed within a certain unit of time. It is a measure that reflects mental efficiency.

    Time frame: Baseline and 8-weeks (post intervention)

  8. Change from Baseline NIH Toolbox Picture Sequence Memory Test at 8-weeks (post-intervention)

    Test of episodic memory - the acquisition, storage and retrieval of new information. It involves conscious recollection of information learned within a context.

    Time frame: Baseline and 8-weeks (post intervention)

Secondary outcomes

  1. Change from Baseline Multiple Sclerosis Self-Management Scale (MSSM) at 8-weeks (post-intervention)

    A 24-item self-report instrument developed specifically to address self-management in persons with MS.

    Time frame: Baseline and 8-weeks (post intervention)

  2. Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Medications and Treatments 4a at 8-weeks (post-intervention)

    A 4-item self-report measure of confidence in managing medication schedules of different complexity. Items also assess managing medication and other treatments in challenging situations such as when traveling, when running out of medication, and when adverse effects are encountered.

    Time frame: Baseline and 8-weeks (post intervention)

  3. Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Symptoms 4a at 8-weeks (post-intervention)

    A 4-item self-report measure of confidence to manage/control symptoms, to manage symptoms in different settings (home, public place, an unfamiliar place) and to keep symptoms from interfering with work, sleep, relationships or recreational activities.

    Time frame: Baseline and 8-weeks (post intervention)

  4. Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Daily Activities 4a at 8-weeks (post-intervention)

    A 4-item self-report measure of confidence in performing various activities of daily living (ADLs) without assistance. Items also assess exercise, sexual activities and managing activities in challenging situations (traveling, bad weather).

    Time frame: Baseline and 8-weeks (post intervention)

  5. Change from Baseline Neuro-Quality of Life (QoL) Short Form v2.0 - Cognitive Function at 8-weeks (post-intervention)

    An 8-item self-report measure of mental acuity, concentration, verbal and nonverbal memory, verbal fluency, and perceived changes in these cognitive functions.

    Time frame: Baseline and 8-weeks (post intervention)

  6. Change from Baseline Neuro-QoL Short Form v1.0 - Depression at 8-weeks (post-intervention)

    An 8-item self-report measure of negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), as well as decreased positive affect and engagement (loss of interest, meaning, and purpose). Somatic symptoms (changes in appetite, sleeping patterns) are not included, which eliminates consideration of these items' confounding effects when assessing patients with comorbid physical conditions. Assesses depression over the past seven days.

    Time frame: Baseline and 8-weeks (post intervention)

  7. Change from Baseline Neuro-QoL Short Form v1.0 - Fatigue at 8-weeks (post-intervention)

    An 8-item self-report measure of fatigue symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. Assesses fatigue over the past seven days.

    Time frame: Baseline and 8-weeks (post intervention)

  8. Change from Baseline Neuro-QoL Short Form v1.0 - Sleep Disturbance 4a at 8-weeks (post-intervention)

    An 8-item self-report measure of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. Sleep Disturbance does not focus on symptoms of specific sleep disorders, nor does it provide subjective estimates of sleep quantities (total amount of sleep, time to fall asleep, amount of wakefulness during sleep). Assesses sleep disturbance over the past seven days.

    Time frame: Baseline and 8-weeks (post intervention)

  9. Change from Baseline Physical Activity - steps at 8-weeks (post-intervention)

    Accelerometer step count

    Time frame: Baseline and 8-weeks (post intervention)

  10. Change from Baseline Physical Activity - activity count at 8-weeks (post-intervention)

    Accelerometer activity count

    Time frame: Baseline and 8-weeks (post intervention)

  11. Change from Baseline Sleep quality - sleep latency at 8-weeks (post-intervention)

    Accelerometer sleep latency

    Time frame: Baseline and 8-weeks (post intervention)

  12. Change from Baseline Sleep quality - wake after sleep onset at 8-weeks (post-intervention)

    Accelerometer wake after sleep onset

    Time frame: Baseline and 8-weeks (post intervention)

  13. Change from Baseline Sleep quality - total sleep time at 8-weeks (post-intervention)

    Accelerometer total sleep time

    Time frame: Baseline and 8-weeks (post intervention)

  14. Change from Baseline Sleep quality - sleep efficiency at 8-weeks (post-intervention)

    Accelerometer sleep efficiency

    Time frame: Baseline and 8-weeks (post intervention)

06

Study locations

1 site
  • The University of Texas at Austin
    Austin, Texas 78701, United States
07

References and documents

Study documents

  • Study protocol · Sep 19, 2017
  • Statistical analysis plan · Sep 19, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — There is no plan to share individual participant data from this pilot study

08

Registry details

Key details

Study ID
NCT03458767
Lead sponsor
University of Texas at Austin
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Oct 9, 2017
Primary completion
Jun 1, 2018
Completion
Jun 1, 2018
Last update
Jul 17, 2018

Study contacts

Janet D Morrison, PhD
principal investigator · The University of Texas at Austin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion